Drugmaker Novo Nordisk is providing refunds to 340B covered entities on its blockbuster diabetes/weight loss drug Ozempic and three other products.

Novo Nordisk To Provide Refunds on Ozempic and Three Other Drugs to 340B Entities

Drugmaker Novo Nordisk announced it is providing 340B covered entities 12-months-worth of refunds on four drug products including two of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.